๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Beijing
Clinical trial register · China

Clinical Trials in Beijing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Peking Union Medical College Hospital276 Beijing Tiantan Hospital214 Cancer Institute and Hospital, Chinese Academy of Medical Sciences197 AstraZeneca183 Peking University People's Hospital158
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Beijing

5484 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
A Study of GNC-077 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors
NCT06755242Gastrointestinal Tumors, Solid Tumor
DrugGNC-077
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
20
Beijing
2025-01
Not yet open
An Exploratory Clinical Study of a Low-dose Buprenorphine Patch for the Treatment of Autism Spectrum Disorders
NCT06772324Autism Spectrum Disorder
Peking University Sixth Hospital
Not applicable
60
Beijing
2025-01
Not yet open
Diagnostic Performance of Contrast-Enhanced Mammography
NCT06713915Mammography
ZHOU Yidong
Observational
600
Beijing
2025-01
Not yet open
A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases
NCT06774664IgA Nephropathy
DrugSCTC21C
Sinocelltech Ltd.
Phase 1/2
99
Baotou, Beijing, Chengdu, Guangzhou, Hangzhou, Jinan, Nanchang, Nanning
2025-01
Not yet open
Tranexamic Acid with Intensive Blood Pressure Management in Ultra-Early Intracerebral Hemorrhage
NCT06760078Spontaneous Intracranial Hemorrhage, Hypertension
Xuanwu Hospital, Beijing
Phase 4
532
Beijing
2024-12-31
Recruiting
CVI Alterations in FD: a Prospective, Multicenter, Observational Cohort Study
NCT06512571Fabry Disease, Cardiac Variant
China National Center for Cardiovascular Diseases
Observational
300
Beijing
2024-12-31
Recruiting
A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors
NCT06581419Advanced Malignant Neoplasm, Advanced or Metastatic Non-small Cell Lung Cancer
DrugIAP0971
SUNHO๏ผˆChina๏ผ‰BioPharmaceutical CO., Ltd.
Phase 1/2
78
Beijing
2024-12-31
Recruiting
The Effects of Xuezhikang and Atorvastatin on Lipid in Patients With Dyslipidemia and Prediabetes
NCT06750783Prediabetic State (IGT)
DrugAtorvastatin
Beijing Tsinghua Chang Gung Hospital
Phase 4
398
Beijing
2024-12-31
Active, closed
A Clinical Study of TQC2731 Injection in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
NCT06707883Chronic Obstructive Pulmonary Disease
DrugTQC2731
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 2
258
Chuzhou, Hefei, Huainan, Beijing, Lanzhou, Foshan, Guangzhou, Jiangmen
2024-12-31
Recruiting
Effect of Mobile-Based Home Cardiac Rehabilitation on Coronary Plaque
NCT07660419Coronary Artery Disease (CAD), Coronary Stenosis
China National Center for Cardiovascular Diseases
Not applicable
176
Beijing
2024-12-31
Not yet open
Study to Evaluate the Efficacy and Safety of MY008211A in Subjects with Primary Immunoglobulin a Nephropathy (IgAN)
NCT06687174IgA Nephropathy (IgAN)
DrugMY008211A
Wuhan Createrna Science and Technology Co., Ltd
Phase 2
72
Beijing
2024-12-31
Recruiting
Effectiveness of Personalized Alternating Current Stimulation for Treating Cognitive Impairment in CNS Demyelination Patients
NCT06968039Multiple Sclerosis, Electric Stimulation
Xuanwu Hospital, Beijing
Not applicable
85
Beijing
2024-12-31
Not yet open
Efficacy and Safety of Changkang Granules in the Treatment of Irritable Bowel Syndrome With Predominant Diarrhea (Liver qi Affecting the Spleen Pattern)
NCT06753890Diarrhea-predominant Irritable Boewl Syndrome
Tasly Pharmaceutical Group Co., Ltd
Phase 3
520
Baoding, Beijing, Changsha, Chengde, Chengdu, Guangzhou, Hangzhou, Kaifeng
2024-12-30
Active, closed
A Clinical Study of HT-101 and/or HT-102 in Patients With Chronic Hepatitis B Virus Infection
NCT07183306Chronic Hepatitis B
DrugsHT-101·HT-102
Suzhou HepaThera Biotech Co., Ltd.
Phase 1/2
86
Beijing, Xiamen, Guangzhou, Qingyuan, Shanghai, Chengdu
2024-12-30
Active, closed
A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Obese/Overweight Subjects
NCT06728124Obesity/Overweight
DrugGZR18
Gan & Lee Pharmaceuticals.
Phase 3
630
Beijing
2024-12-30
Not yet open
QR12000 Compound Tablets in Patients with Moderate to Severe Essential Hypertension
NCT06716970Essential Hypertension
DrugSacubitril/valsartan
Wuhan Createrna Science and Technology Co., Ltd
Phase 3
810
Beijing
2024-12-30
Not yet open
Targeted TDCS Intervention for Internet Gaming Disorder
NCT06759051Internet Gaming Disorder
Peking University
Not applicable
180
Beijing
2024-12-30
Recruiting
Phase 1/II Clinical Study of SYS6043 in the Treatment of Advanced/Metastatic Solid Tumors
NCT07415863Advanced/Metastatic Solid Tumors
DrugSYS6043
CSPC Megalith Biopharmaceutical Co.,Ltd.
Phase 1/2
820
Beijing
2024-12-30
Not yet open
Photoplethysmography (PPG) Algorithm With Smartwatch in Evaluation of Atrial Fibrillation Burden
NCT06686940Atrial Fibrillation (AF)
Beijing Anzhen Hospital
Observational
10,000
Beijing
2024-12-30
Recruiting
Effectiveness of Personalized Alternating Current Stimulation for Treating Emotional Disorders in CNS Demyelination Patients
NCT06933537Idiopathic Inflammatory Demyelinating Disorders of the Central Nervous System
Xuanwu Hospital, Beijing
Not applicable
65
Beijing
2024-12-29
Recruiting
A Phase Ib Study of JMKX000197 Injection in the Treatment of Malignant Pleural Effusion
NCT06740019Malignant Pleural Effusions (Mpe)
DrugJMKX000197
Jemincare
Phase 1
30
Beijing
2024-12-28
Active, closed
Efficacy and Safety of ZVS101e in Patients With Bietti 's Crystalline Dystrophy
NCT06743646Bietti Crystalline Corneoretinal Dystrophy, Bietti Crystalline Dystrophy
DrugZVS101e
Chigenovo Co., Ltd
Phase 3
62
Beijing, Guangzhou, Haerbin, Zhengzhou, Shanghai, Chengdu, Tianjin, Wenzhou
2024-12-27
Recruiting
Study of ISM6331 in Participants With Advanced/Metastatic Mesothelioma or Other Advanced Solid Tumors
NCT06566079Malignant Mesothelioma, Metastatic Malignant Solid Tumor, Advanced Solid Tumor
InSilico Medicine Hong Kong Limited
Phase 1/2
160
Zhengzhou, Shanghai, Beijing, Guangzhou
2024-12-27
Active, closed
A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)
NCT06593522MTAP-deleted NSCLC
DrugAnvumetostat
Amgen
Phase 2
61
Beijing, Fuzhou, Zhengzhou, Wuhan, Changsha, Changchun, Jinan, Shanghai
2024-12-26
Recruiting
A Phase I Study of HY-2003 in the Subjects With Excessive Submental Fat Accumulation
NCT06756490Moderate or Severe Submental Fullness
Sichuan Huiyu Pharmaceutical Co., Ltd
Phase 1
30
Beijing, Xi'an
2024-12-26
Recruiting
A Long-term Follow-up Study of Subjects Enrolled in Clinical Trials of Cadonilimab (AK104)
NCT07547787Locally Advanced Unresectable or Metastatic Gastric Cancer
Akeso
Observational
610
Beijing
2024-12-26
Recruiting
BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases
NCT06794008Systemic Lupus Erythematosus, Inflammatory Myopathy, Systemic Sclerosis (SSc), ANCA-associated Vasculitis
Peking University People's Hospital
Phase 2
50
Beijing
2024-12-26
Recruiting
A Phase I/II Clinical Study of CTS3497 in Patients With MTAP Deficient Malignacies
NCT06971523Solid Tumor, Lymphoma
CytosinLab Therapeutics Co., Ltd.
Phase 1/2
224
Beijing
2024-12-25
Recruiting
The Regression Pattern of Primary Lesions in Lung Cancer After Definitive Radiotherapy
NCT06692972Lung Cancer
China-Japan Friendship Hospital
Observational
500
Beijing, Wuhan
2024-12-25
Recruiting
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RAG-17 in Subjects With Amyotrophic Lateral Sclerosis (ALS) With Superoxide Dismutase Type 1 (SOD1) Gene Mutation
NCT06556394Amyotrophic Lateral Sclerosis
Ractigen Therapeutics.
Phase 1
32
Beijing, Chengdu, Hangzhou
2024-12-24
Active, closed
Endovascular Treatment or Standard Medical Care for Cerebral Venous Sinus Thrombosis(ESCORT)
NCT06583889Cerebral Venous Sinus Thrombosis
DrugHeparin
Beijing Tiantan Hospital
Not applicable
224
Beijing
2024-12-24
Recruiting
Sirolomus Adjuvant Treatment of Focal Refractory Epilepsy (SATFRE)
NCT06719791Epilepsy, Drug Resistant
Xuanwu Hospital, Beijing
Phase EARLY_PHASE1
15
Beijing
2024-12-23
Recruiting
A Clinical Study to Evaluate the Efficacy, Tolerability, and Safety of Bempedoic Acid
NCT06780410Primary Hyperlipidemia
Gan & Lee Pharmaceuticals.
Phase 3
240
Beijing
2024-12-20
Active, closed
Anti-CEACAM5 ADC Precemtabart Tocentecan (M9140) in Chinese Participants With Solid Tumors
NCT06806046Solid Tumors, Colorectal Cancer
DrugM9140
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 1
12
Beijing, Guangzhou, Hangzhou
2024-12-20
Recruiting
A Study of GC101 TIL in Advanced Melanoma
NCT06703398Melanoma
DrugCisplatin
Shanghai Juncell Therapeutics
Phase 2
98
Beijing
2024-12-20
Recruiting
Clinical and Metabolomics Studies on the Improvement of Ovarian Reserve by Acupoint Photodynamic Therapy and Traditional Chinese Medicine Treatment
NCT07376824Diminished Ovarian Reserve (DOR)
Peking Union Medical College Hospital
Phase 3
90
Beijing
2024-12-20
Active, closed
Efficacy and Safety of OsrhCT and Dimethicone Emulsion Before Upper Endoscopy on Visualization of the Gastric Mucosa.
NCT06722664Gastric Mucosal Lesion
Healthgen Biotechnology Corp.
Phase 2
336
Beijing, Wuhan, Hohhot
2024-12-19
Recruiting
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
NCT06736574Heart Failure, Heart Failure With Reduced Ejection Fraction
Cytokinetics
Phase 3
1,800
Beijing, Lanzhou, Guangzhou, Shenzhen, Nanning, Luoyang, Changsha, Chifeng
2024-12-19
Recruiting
A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease
NCT06500702Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion
DrugsBrivekimig·Rilzabrutinib·Frexalimab
Sanofi
Phase 2
84
Beijing, Chengdu, Shanghai
2024-12-19
Recruiting
ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
NCT06656494Acute Myelogenous Leukemia, Myelodysplastic Syndromes (MDS)
DrugsICP-248·Azacitidine
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 1
266
Hefei, Beijing, Chongqing, Guangzhou, Zhengzhou, Wuhan, Suzhou, Nanchang
2024-12-18
Not yet open
Aumolertinib Versus Osimertinib As First-line Therapy for Patients with EGFR Mutated Locally Advanced or Metastatic Non-small-cell Lung Cancer
NCT06752408Non Small Cell Lung Cancer
DrugsAumolertinib·Osimertinib
Peking Union Medical College Hospital
Phase 2
316
Beijing
2024-12-17
Recruiting
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
NCT06679101Multiple Myeloma, Newly Diagnosed Multiple Myeloma
DrugsBelantamab mafodotin·Daratumumab·Lenalidomide·Dexamethasone
GlaxoSmithKline
Phase 3
520
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Nanchang, Nanjing, Shanghai
2024-12-16
Recruiting
A Study of Maribavir in Chinese Adults With Cytomegalovirus (CMV) Infections
NCT06439342Cytomegalovirus (CMV)
DrugMaribavir
Takeda
Phase 3
20
Hefei, Chongqing, Guangzhou, Zhengzhou, Wuhan, Suzhou, Beijing, Tianjin
2024-12-16
Recruiting
Autologous BCMA-targeted CAR-T Cell Injection for Relapsed/Refractory Light Chain Amyloidosis
NCT07626476Relapsed/Refractory Light Chain Amyloidosis, AL Amyloidosis, Systemic Light Chain Amyloidosis
Beijing Boren Hospital
Phase EARLY_PHASE1
30
Beijing
2024-12-16
Recruiting
Study on the Mechanism of Cognitive Impairment in Patients with Moyamoya Disease
NCT06832839Moyamoya Disease
Beijing Tiantan Hospital
Observational
360
Beijing
2024-12-16
Recruiting
Multicenter Real-World Cohort Study Evaluating the Impact of Early Intensive Lipid-Lowering Therapy on the Prognosis of Acute Coronary Syndrome Patients(ELITE-ACS)
NCT06738758Acute Coronary Syndromes
DrugEvolocumab
Yun Dai Chen
Observational
6,000
Beijing
2024-12-16
Recruiting
Long-term Follow-up Registry Study of Equecabtagene Autoleucel Injection
NCT07028970Multiple Myeloma
Nanjing IASO Biotechnology Co., Ltd.
Observational
1,500
Beijing, Tianjin, Wuhan, Zhengzhou
2024-12-15
Recruiting
Clinical Study of IM96 CAR-T Cell Therapy in Patients With Advanced Colorectal Cancer
NCT06718738Colorectal Cancer (CRC)
Beijing Immunochina Medical Science & Technology Co., Ltd.
Phase 1
9
Beijing
2024-12-15
Recruiting
Effects of Transcranial Electrical Stimulation on Cognitive Impairment in CNS Inflammatory Demyelinating Diseases
NCT07029386Idiopathic Inflammatory Demyelinating Disorders of the Central Nervous System
Xuanwu Hospital, Beijing
Not applicable
40
Beijing
2024-12-15
Recruiting
Study on Evaluating the Effectiveness of Statins in the Treatment of Moyamoya Disease
NCT06817434Moyamoya Disease
Beijing Tiantan Hospital
Observational
330
Beijing
2024-12-15
Recruiting
TACE Combined With Lenvatinib and PD-1 Inhibitor for Ruptured Hepatocellular Carcinoma
NCT06740370Hepatocellular Carcinoma, Transcatheter Arterial Chemoembolization, Anti-PD1 Antibody, Lenvatinib
DrugsLenvatinib·Nivolumab
Sun Yat-sen University
Not applicable
32
Beijing
2024-12-13
Active, closed
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
NCT06628310Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
DrugsBudigalimab·Telisotuzumab Adizutecan·Leucovorin·Oxaliplatin
AbbVie
Phase 2
185
Beijing, Langfang, Harbin, Wuhan, Hangzhou
2024-12-13
Recruiting
Normobaric Oxygen in AIS Transferred for EVT
NCT06666764Ischemic Stroke
Capital Medical University
Phase 3
1,500
Beijing, Fuzhou, Ningde, Putian, Zhangzhou, Guangzhou, Hezhou, Cangzhou
2024-12-13
Recruiting
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
NCT06750094Colorectal Neoplasms
DrugsLeucovorin calcium/Levoleucovorin·Amivantamab·Irinotecan·Pemetrexed
Janssen Research & Development, LLC
Phase 3
700
Beijing, Changchun, Changsha, Chengdu, Ganzhou, Guangzhou, Hangzhou, Harbin
2024-12-12
Recruiting
Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer
NCT06584032Advanced Endometrial Cancer
DrugsFruquintinib·Doxorubicin·Sintilimab·Paclitaxel
Hutchmed
Phase 3
412
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Changsha
2024-12-12
Recruiting
A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of MK-6204 (SKB535) for Injection in Participants With Advanced Solid Tumors
NCT06726369Advanced Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 1
90
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Shanghai, Wuhan
2024-12-12
Recruiting
A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)
NCT06716606Connective Tissue Diseases
DrugBelimumab
GlaxoSmithKline
Phase 3
514
Beijing, Chengdu, Hangzhou, Mianyang, Shanghai, Shenyang, Zhuzhou
2024-12-12
Recruiting
A Study of SIGX1094R in Patients With Advanced Solid Tumors
NCT06739291Advanced Solid Tumors
Signet Therapeutics
Phase 1
102
Beijing
2024-12-12
Recruiting
A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.
NCT05421858Candidemia, Candidiasis, Invasive
DrugsCaspofungin·Fosmanogepix·Fluconazole
Basilea Pharmaceutica
Phase 3
450
Beijing, Bengbu, Chengdu, Guangzhou, Hangzhou, Lishui, Liuzhou, Nanchang
2024-12-11
Recruiting
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06588855Moderately to Severely Active Ulcerative Colitis
DrugAfimkibart
Hoffmann-La Roche
Phase 3
350
Beijing, Kunming, Changsha, Chengdu, Guangzhou, Hangzhou, Huizhou, Nanchang
2024-12-11
Recruiting
Impact of Severe Obstructive Sleep Apnea-Hypopnea Syndrome on Auditory-Cognitive Processing
NCT07039500Obstructive Sleep Apnea, Auditory Processing Disorder
Peking University First Hospital
Observational
100
Beijing
2024-12-11
Not yet open
Evaluating an Insulin Pump for Time in Range (TIR) in Patients with Type 1 Diabetes
NCT06741943Type 1 Diabetes Mellitus, Insulin Pump, Time in Range
Tao Yuan๏ผŒMD
Not applicable
60
Beijing
2024-12-11
Recruiting
Ultrasound-guided Thermal Ablation for Papillary Thyroid Carcinoma
NCT06733740Papillary Thyroid Cancer
Chinese PLA General Hospital
Observational
3,000
Beijing
2024-12-10
Recruiting
iGlarLixi CGM Study in Chinese T2D Individuals After OADs
NCT06671587Type 2 Diabetes (T2D)
DrugIGlarLixi
Sanofi
Phase 4
678
Beijing
2024-12-10
Not yet open
Medial Enhancement Technique for the Treatment of Old Femoral Neck Fractures
NCT06713031Fracture of Neck of Femur
Chinese PLA General Hospital
Not applicable
400
Beijing
2024-12-10
By invitation
A Study to Evaluate the Efficacy and Safety of HSK31858 Tablets in Patients with Airway Mucus Hypersecretion
NCT06820749Asthma Bronchiale, Bronchiectasis, Chronic Obstructive Pulmonary Disease (COPD)
DrugHSK31858
Haisco Pharmaceutical Group Co., Ltd.
Phase 2
309
Beijing
2024-12-10
Recruiting
Clinical Study of a Novel Sliding Compression Locking Plate in the Treatment of Fresh Femoral Neck Fractures
NCT06713291Fracture of Femoral Neck
Chinese PLA General Hospital
Not applicable
1,150
Beijing
2024-12-10
Not yet open
Orthopedic Intelligent Navigation System in the Treatment of Fresh Femoral Neck Fractures
NCT06713018Fracture of Neck of Femur
Chinese PLA General Hospital
Not applicable
300
Beijing
2024-12-10
Recruiting
Establishment and Clinical Transformation of ADC Drug Efficacy Evaluation System for Breast Cancer Based on Molecular Imaging
NCT06715020Breast Cancer
Drug18F-FDG
Peking University Cancer Hospital & Institute
Not applicable
60
Beijing
2024-12-10
Recruiting
Ultrasound-guided Thermal Ablation for Bethesda III/IV Thyroid Nodules
NCT06733753Thyroid Nodule
Chinese PLA General Hospital
Observational
600
Beijing
2024-12-09
Recruiting
Ultrasound-guided Thermal Ablation for Recurrent Thyroid Cancer
NCT06733766Recurrent Thyroid Cancer
Chinese PLA General Hospital
Observational
300
Beijing
2024-12-09
Recruiting
Long-term Follow-up Study of AL-001 Ophthalmic Injection in Subjects with WAMD
NCT06718816Wet Age-related Macular Degeneration (wAMD)
Beijing Anlong Biopharmaceutical Co., Ltd.
Observational
21
Beijing
2024-12-09
Recruiting
Predictive Value of Myelodysplastic Syndrome Stem Cells Determined by Multiparameter Flow Cytometry
NCT06569095Myelodysplastic Syndromes
Peking University People's Hospital
Observational
163
Beijing, Wuhan, Zhengzhou
2024-12-09
Recruiting
Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia
NCT06597019Familial Hypercholesterolemia - Heterozygous
DrugInclisiran
Novartis Pharmaceuticals
Phase 3
60
Beijing, Shanghai
2024-12-09
Recruiting
Ultrasound-guided Thermal Ablation for Benign Thyroid Nodules
NCT06729762Thyroid Nodule (Benign)
Chinese PLA General Hospital
Observational
1,500
Beijing
2024-12-09
Recruiting
A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors
NCT06625593Advanced Solid Tumor
BeOne Medicines
Phase 1
168
Bengbu, Hefei, Beijing, Fuzhou, Xiamen, Nanning, Shijiazhuang, Harbin
2024-12-09
Recruiting
A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease
NCT06679140COVID-19 SARS-CoV-2 Infection
DrugIbuzatrelvir
Pfizer
Phase 3
2,330
Chizhou, Beijing, Xiamen, Guangzhou, Nanning, Changsha, Nanchang, Changchun
2024-12-08
Active, closed
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD0780 in Participants With Dyslipidaemia
NCT06834932Dyslipidaemia
AstraZeneca
Phase 2/3
432
Baotou, Beijing, Bengbu, Changchun, Changde, Changsha, Changzhou, Chengdu
2024-12-06
Recruiting
A Phase III Clinical Trial for Efficacy and Safety Evaluation of JP-1366 Tablets on Reflux Esophagitis
NCT06850480Reflux Esophagitis (RE)
Livzon Pharmaceutical Group Inc.
Phase 3
356
Beijing
2024-12-05
Active, closed
Nipocalimab in Moderate to Severe Sjogren's Disease
NCT06741969Sjogrens Syndrome
DrugNipocalimab
Janssen Research & Development, LLC
Phase 3
655
Beijing, Changsha, Changzhou, Chengdu, Dazhou, Ganzhou, Guangzhou, Guiyang
2024-12-04
Recruiting
Hydrocortisone in Hormone Replacement Therapy for Large Pituitary Neuroendocrine Tumors
NCT06679816Pituitary Adenoma, Pituitary Neuroendocrine Tumor
Beijing Tiantan Hospital
Phase 4
882
Beijing
2024-12-04
Recruiting
Exploration of the Dynamic Changes and Mechanisms of the Immune Microenvironment in Advanced Colorectal Cancer Treated With IBI363 Combination Therapy
NCT06946745Immunotherapy
jianming xu
Observational
50
Beijing
2024-12-02
Recruiting
A Study of BGM0504 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise
NCT06716203Type 2 Diabetes Mellitus (T2DM)
DrugBGM0504 Administered
BrightGene Bio-Medical Technology Co., Ltd.
Phase 3
207
Beijing
2024-12-02
Not yet open
Research on the Application of Patient Navigation-based Management Model of Patients After LEEP
NCT06695871Cervical Intraepithelial Neoplasias
Peking University People's Hospital
Not applicable
128
Beijing
2024-12-01
By invitation
Clinical Study of Rhythmic Auditory Stimulation for Gait Disorders
NCT06837038Hemiplegia Due to Stroke, Parkinson Disease, Parkinsonian Syndrome
YiCheng Zhu
Not applicable
60
Beijing
2024-12-01
Recruiting
Intra-arterial Chemotherapy Combined with Radiotherapy and Immunotherapy for HNSCC
NCT06725498Head and Neck Squamous Cell Carcinoma
DrugsAlbumin-Bound Paclitaxel·Cisplatin
Beijing Tongren Hospital
Phase 2
50
Beijing
2024-12-01
Recruiting
Efficacy and Safety of Taitacept in Treatment of Refractory or Recurrent Anti-NMDAR/anti-LGI1 Encephalitis
NCT06510283Anti-N-Methyl-D-Aspartate Receptor Encephalitis
Beijing Tongren Hospital
Phase 2
10
Beijing
2024-12-01
Not yet open
Tofacitinib in Patients With Amyotrophic Lateral Sclerosis
NCT06689982Amyotrophic Lateral Sclerosis
DrugTofacitinib
Beijing Tiantan Hospital
Phase EARLY_PHASE1
12
Beijing
2024-12-01
Recruiting
Minimal Vitrectomy Surgery for Epiretinal Membrane
NCT07019896Epiretinal Membrane, Macular Edema (ME), Nuclear Cataract
Peking Union Medical College Hospital
Not applicable
140
Beijing
2024-12-01
Recruiting
Impact of Recombinant Humanized Type III Collagen on the Immediate and Long-term Effects of Breast Tumor Surgery
NCT06725082Breast Cancer, Collagen Protein
Peking University People's Hospital
Phase 1
30
Beijing
2024-12-01
Active, closed
Treatment Duration of IPA
NCT06583512Invasive Aspergillosis, Antifungal Therapy
Peking University People's Hospital
Observational
15
Beijing
2024-12-01
Recruiting
Evaluation of Targeted Biopsy Plus Sextant Biopsy in Diagnosis of Prostate Cancer
NCT06684652Prostate Cancer
Peking University First Hospital
Not applicable
300
Beijing
2024-12-01
Recruiting
Effects of Sleep Restriction and Stimulus Control in Chronic Insomnia Patients
NCT06658184Chronic Insomnia
Xuanwu Hospital, Beijing
Not applicable
88
Beijing
2024-12-01
Recruiting
Laser Acupuncture for Idiopathic Bell's Palsy
NCT06732622Bell Palsy
Beijing Tongren Hospital
Not applicable
360
Beijing
2024-12-01
Active, closed
The Impact of Targeted Temperature Management Duration on Thrombin Function in Cardiac Arrest Patients
NCT06543849Targeted Temperature Management, Cardiac Arrest, Thrombin Function, Treatment Duration
Tang Ziren
Not applicable
64
Beijing
2024-12-01
Active, closed
Efficacy of Liposomal Bupivacaine Scalp Nerve Block for Postoperative Pain Management After Supratentorial Craniotomy
NCT07344181Postoperative Care
Beijing Tiantan Hospital
Not applicable
118
Beijing
2024-12-01
Recruiting
SCS Therapy for Patients With Bladder and Bowel Dysfunction After SCI
NCT07511244Bladder and Bowel Dysfunction, SCI - Spinal Cord Injury
Beijing Tsinghua Chang Gung Hospital
Not applicable
10
Beijing
2024-12-01
Recruiting
Effects of Cognitive Correction and Stimulus Control in Chronic Insomnia Patients
NCT06658158Chronic Insomnia
Xuanwu Hospital, Beijing
Not applicable
88
Beijing
2024-12-01
Recruiting
Blinatumomab Combined With Low-dose DLI as Maintenance Therapy After Transplantation for B-ALL
NCT07677878ALL (Acute B-Lymphoblastic Leukemia)
DrugBlinatumomab
Liping Dou
Phase 1
60
Beijing
2024-12-01
Recruiting
Exploring Nasal Drop Therapy With Small Extracellular Vesicles for ALS
NCT06598202Amyotrophic Lateral Sclerosis
Xuanwu Hospital, Beijing
Phase 1/2
38
Beijing
2024-12-01
Rows per page Showing 2801–2900 of 5484
Previous 27 28 29 30 31 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/beijing?page=29

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 5,484 of those studies with a site in Beijing.

How many clinical trials are recruiting in Beijing?

3,341 of the 5,484 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 966 have not yet opened recruitment, 1,001 are active but closed to new participants, and 176 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.